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Abstract
Introduction Serum B-type natriuretic peptide (BNP) is
frequently elevated after subarachnoid hemorrhage (SAH), but
whether this high BNP level is related to transient elevation of
left ventricular filling pressure (LVFP) is unknown. However, in
patients with preexistent cardiac pathologies, it is impossible to
differentiate between BNP elevation caused by chronic cardiac
abnormalities and BNP related to acute neurocardiac injury.
Methods All adult patients with SAH admitted to our intensive
care unit were eligible. Patients were excluded for the following
reasons: admission >48 hours after aneurysm rupture, pre-
existing hypertension, or cardiac disease. Levels of BNP and
cardiac troponin Ic were measured daily for 7 days.
Echocardiography was performed by a blinded cardiologist on
days 1, 2, and 7. Doppler signals from the mitral inflow, tissue
Doppler, and the color M-mode–derived flow propagation
velocity (FPV) were obtained to assess echo-estimated LVFP.
Results During a 3-year period, sixty-six consecutive patients
with SAH were admitted. Thirty one patients were studied. The
BNP level was >100 ng/L in 25 patients (80%) during the first
3 days, with a peak on day 2 (median, 126 ng/L) followed by a
gradual decrease (median variation days 1 to 7, 70%). All
patients had an ejection fraction >50%. Early transmitral
velocity/tissue Doppler mitral annular early diastolic velocity was
low: 5.4 (± 1.5) on day 1, 5.8 (± 1.2) on day 2, and 5.1 (± 0.9)
on day 7. Early transmitral velocity/FPV was also low: 1.27 (±
0.4), 1.25 (± 0.3), and 1.1 (± 0.2) on days 1, 2, and 7,
respectively. Cardiac troponin Ic levels ranged from 0 to 3.67
μg/L and were correlated with BNP (r = 0.63, P < 0.01).
Conclusions BNP rises gradually over two days and return to
normal within a week after SAH. Its release is associated with
myocardial necrosis, but is unrelated to elevated LVFP assessed
by echocardiography.
Introduction
Serum plasma B-type natriuretic peptide (BNP) is a global
indicator of left cardiac dysfunction. Recent reports have
shown the contribution of left ventricular (LV) diastolic function
to plasma BNP levels and the usefulness of BNP in the diag-
nosis of diastolic dysfunction [1]. Stretch of cardiomyocytes
due to elevated filling pressures is reported to be the most
important stimulus of BNP regulation [2]. Doppler echocardi-
ography, color flow imaging, and myocardial tissue imaging
can assess intrinsic diastolic function and estimate left ven-
tricular filling pressure (LVFP) or pulmonary capillary wedge
pressure with accuracy over a wide range of ejection fraction
(EF) [3,4], including normal EF [5].
A: late transmitral velocity; ABS: apical ballooning syndrome; BNP: B-type natriuretic peptide; cTi: troponin Ic; DT: deceleration time of E velocity; E: 
early transmitral velocity; Ea: tissue Doppler imaging early diastolic velocity; ELISA: enzyme-linked immunosorbent assay; FPV: color M-mode-derived 
flow propagation velocity; ICU: intensive care unit; IVRT: isovolumic relaxation time; LV: left ventricular; LVEF: left ventricular ejection fraction; LVFP: 
left ventricular filling pressure; PAP: pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; SAH: subarachnoid hemorrhage; WFNS: 
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In patients with subarachnoid hemorrhage (SAH), the BNP
level increases soon after aneurysm rupture and returns to
baseline in one to two weeks [6-8]. The source of BNP release
remains controversial [9]. However, the most likely cause of
BNP increase after SAH is cardiac injury [10]. Cardiac injury
is a well-recognized phenomenon after SAH and results in
ECG changes [11], serum elevation of troponin Ic (cTi)
[12,13], and LV systolic and diastolic dysfunction [14]. A car-
diac source of BNP is also supported by a recent study dem-
onstrating that cardiac injury and dysfunction occurring early
after SAH are associated with elevated plasma BNP levels
[10].
To answer a fundamental question, the hypothesis of the
present study was that BNP elevation after SAH is triggered
by a transient elevation of LVFP due to diastolic dysfunction.
Nevertheless, in patients with heart disease it is impossible to
know the baseline levels of BNP. Consequently, it is impossi-
ble to differentiate between BNP elevation caused by pre-
existent chronic diastolic dysfunction with elevated filling pres-
sures, and BNP increase in parallel with acute cardiac dys-
function caused by SAH. Therefore, this study was strictly
limited to patients without pre-existing cardiac disease and
without history of chronic hypertension, which is frequent
before aneurysm rupture [15] and may be responsible for pre-
existing diastolic dysfunction and BNP elevation.
The aim of this prospective cohort study of recent SAH
patients (<48 hours) was to accurately quantify the incidence,
time course, and recovery patterns of BNP and LVFP by using
serial echocardiographic measurements during the first week
after aneurysm rupture.
Materials and methods
Study design
This study was conducted in the intensive care unit (ICU) of
the Military Teaching Hospital Sainte-Anne during a 36-month
period between June 2004 and June 2007. The Military
Teaching Hospital Sainte-Anne is the only neurosurgical hos-
pital in the region of Var, which has a population of one million
inhabitants. The study was approved by our local ethics com-
mittee, and all patients or next of kin provided written, informed
consent.
Eligibility criteria for inclusion were the following: SAH related
to a ruptured aneurysm documented by angiography; age over
18 years; and sinus rhythm 60 to 100 beats/min. Patients with
chronic hypertension (history, antihypertensive treatment),
heart disease such as cardiomyopathy, or prior myocardial inf-
arction or atrial fibrillation (history, electrocardiogram, treat-
ment) were not included. Patients, families, or referring
physicians were interviewed to determine the date and nature
of the first signs or symptoms which were clearly those of
SAH. If delay from first sign or symptom to arrival at our ICU
was more than 48 hours after aneurysm rupture symptoms,
patients were not included. Patients who died before day 7
were excluded because of lack of parameters concerning the
evolution of diastolic parameters and echo-estimated LVFP.
Patients, management, and clinical data collection
All patients were admitted to our unit for a seven-day period
and were managed according to the recommendations of the
French Society for Anesthesia and Intensive Care [16]. In par-
ticular, the culprit cerebral aneurysm identified by angiography
was treated as soon as possible by either endovascular coiling
or neurosurgical clipping, depending on individual anatomy. All
patients underwent transcranial Doppler evaluation once a
day.
Conscious patients were managed with bed rest, continuous
infusion of nimodipine at a rate of 2 mg/hour, phenytoine, anal-
gesia (paracetamol, nefopam), and a proton pump inhibitor.
Management of comatose patients included sedation, ventila-
tion, enteral nutrition, nimodipine, and monitoring of intracra-
nial pressure in the case of intracranial hypertension.
All patients were managed according to a standard protocol.
Prophylactic hypervolemia was not used, but, on the contrary,
our protocol was rather restrictive to avoid BNP elevation as a
result of iatrogenic volume overload from therapeutic hypervo-
lemia. During the first seven days, each patient received isot-
onic saline intravenous fluid ranging from 30 to 40 ml/kg/day.
Fluid balance was calculated daily. Measurements of natremia
and sodium balance were performed daily. If necessary, treat-
ment of elevated intracranial pressure included mannitol, but
not hypertonic saline. In patients with vasospasm, hematocrit
target (30 to 35%) was employed for hypervolemia using addi-
tional intravenous infusion of isotonic saline for the purpose of
intravascular volume expansion. The mean arterial blood pres-
sure was maintained at a mean arterial pressure of 100 to 110
mmHg.
When intracranial hypertension occurred, norepinephrine was
used to maintain cerebral perfusion pressure above 65 mmHg.
Vasospasm was managed by moderate hypervolemic hyper-
tension and intracranial angioplasty when possible.
Clinical and demographic data including age, sex, body mass
index, and body surface area were collected. The fluid balance
(fluid intake – urine volume – insensible losses) was calculated
at 24-hour intervals. Insensible losses per day were estimated
at 700 ml for all patients. Creatinine clearance was computed
from creatinine excretion in a 24-hour urine collection and a
single measurement of serum creatinine on day 2.
Aneurysm location was noted, and the neurological status was
assessed at the time of admission and graded according to
the World Federation of Neurosurgical Societies (WFNS)
scale and the Fisher score. The presence or absence of cere-
bral vasospasm by imaging (transcranial Doppler and cerebralAvailable online http://ccforum.com/content/13/3/R76
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angiography) during the seven days was noted. In addition, the
use of norepinephrine to maintain arterial pressure or cerebral
perfusion pressure during the first three days was recorded.
Data regarding aneurysmal treatment and neurological events
(rebleeding, hydrocephalus, vasospasm) were recorded.
Hyponatremia was defined as a sodium level of less than 135
mEq/L for at least two consecutive days.
ECG and cardiac troponin Ic
A 12-lead ECG was performed daily for seven days. The
ECGs were considered abnormal if the T wave was inverted
or flattened, the S-T segment was elevated or depressed, the
QT interval was prolonged, or arrhythmia was present.
Measurement of cTi was performed daily for seven days in all
patients. The serum cTi levels were measured by ELISA (refer-
ence range for upper limit of normal, 0.14 μg/l; lower limit of
detection, 0.04 μg/l) with a Siemens® (Deerfield, IL, USA) ana-
lyzer.
BNP determination
Arterial blood was drawn daily for seven days from patients
and placed in a Vacutainer tube containing potassium EDTA.
Within 30 minutes, the blood was placed on a Triage B-Type
Natriuretic Peptide test slide (Biosite®  Diagnostics, San
Diego, CA, USA) and analyzed in the Biosite MeterPlus
machine, a point-of-care test based on fluorescence immu-
noassay. The test has a range of 5 to 5000 ng/l.
Echocardiography and Doppler
Transthoracic echocardiography was performed on days 1
(day of admission), 2, and 7 with an ACUSON CV 70® ultra-
sound system (Siemens® CO, Erlangen, Germany) equipped
with 2.5-MHz transducers. All Doppler echocardiography
studies were performed by a single experienced cardiologist
blinded to all clinical, hemodynamic, and BNP data.
Patients were imaged in the supine position. Two-dimensional
images were obtained in the standard parasternal and apical
views. All echocardiographic data were averaged from three to
five end-expiratory cycles. Left ventricular and left atrial dimen-
sions were measured according to the recommendations of
the American Society for Echocardiography. Left ventricular
mass was calculated by Devereux's formula and indexed for
body-surface area. LVEF was measured by Simpson's
method. An LVEF more than 50% was defined as normal; an
LVEF less than 50% was defined as reduced.
All Doppler recordings were obtained at a sweep speed of
100 mm/s. Pulsed Doppler was used to record transmitral
flow in the apical four-chamber view. Tissue Doppler velocities
were acquired at a lateral annular site. Mitral inflow measure-
ments included early peak (E) and late peak (A) velocities, E/
A ratio, and deceleration time (DT) of E velocity. These meas-
urements were analyzed as described previously [4]. Color M-
mode-derived flow propagation velocity (FPV) was measured
as the slope of the linear component of the color border pro-
duced by propagation of E velocity into the left ventricle past
the mitral valve tips [17]. On tissue Doppler imaging record-
ings, early diastolic velocities (Ea) were measured. The com-
bined indices E/FPV [17] and E/Ea [4] were computed (Figure
1). Isovolumic relaxation time (IVRT) was measured from the
end of aortic flow to the onset of mitral inflow after placing the
5 mm pulsed Doppler sample volume between the mitral valve
and the LV outflow in an apical five-chamber view. The systolic
pulmonary artery pressure (PAP) was estimated using contin-
uous-wave Doppler ultrasound measurement of the peak
velocity of a tricuspid regurgitant jet.
Statistical analysis
Statistical analysis was performed using SPSS version 15.0
(SPSS Inc., Chicago, IL, USA). Continuous variables were
expressed as mean ± standard deviation or as median with
interquartile range. The non-parametric Mann-Whitney U test
was used to compare two groups. Correlations between
parameters were calculated by using Spearman's correlation
coefficient. For all tests, a P < 0.05 was considered signifi-
cant.
Results
During the study period, 66 consecutive patients were admit-
ted to our ICU with SAH related to a ruptured aneurysm that
was documented by angiography. Among them, 29 patients
were excluded from the study. Six patients died during the first
week and were excluded from the final analysis. Therefore,
data from 31 patients were analyzed (Figure 2).
Patients characteristics, fluid, and sodium balance
Patient characteristics and clinical events are shown in Tables
1 and 2. All six cases of vasospasm occured after day 5. Fuid
balance, sodium balance, and natremia until day 4 are shown
in Table 3. Hyponatremia was present in three cases. The
median daily fluid balance was negative until day 7. The
sodium balance was close to zero until day 7. The sodium and
fluid balance were not different in patients with BNP more than
100, 150, or 250 ng/L. Renal function was normal: mean
serum creatinine of 56 (± 15) μmol/L and mean measured cre-
atinine clearance of 140 (± 60) ml/min.
BNP time course
Twenty-five patients (80%) had a BNP level of more than 100
ng/L during the first three days. The peak BNP level was
observed on day 2, with a median level of 126 ng/L (interquar-
tile range, 53 to 202 ng/L; Figure 3). In four patients, no BNP
increase was observed. The median variation in BNP (between
a peak on day 1 or 2 and day 7) was 70% (interquartile range,
41 to 92%). On day 7, 27 patients (87%) had a BNP level less
than 100 ng/L. Age was not correlated with BNP level. With
regard to the BNP increase, there was no significant differ-
ence between patients receiving norepinephrine or not duringCritical Care    Vol 13 No 3    Meaudre et al.
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Figure 1
Echocardiographic parameters to estimate LV filling pressures (a) Mitral inflow, (b) color M-mode-derived flow propagation velocity (FPV), and (c)  Tissue Doppler velocities at the lateral corners of the mitral annulus Echocardiographic parameters to estimate LV filling pressures (a) Mitral inflow, (b) color M-mode-derived flow propagation velocity (FPV), and (c) 
Tissue Doppler velocities at the lateral corners of the mitral annulusAvailable online http://ccforum.com/content/13/3/R76
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the first three days, between patients mechanically ventilated
or not at admission, or between two groups of WFNS scores
(1 versus 2 to 5). However, the median BNP level on day 2
was significantly higher in men than in women (162 ng/L ver-
sus 106 ng/L, P < 0.05). In addition, the median BNP was sig-
nificantly lower in the Fisher group 1 to 2 than in group 3 to 4
on day 2 (100 ng/L versus 144 ng/L, P < 0.05), on day 3 (63
ng/L versus 124 ng/L, P < 0.05), and on day 4 (42 ng/L versus
135 ng/L, P < 0.05).
Echocardiography, filling pressure and diastolic function
Doppler echocardiographic variables are listed in Table 4.
Mitral inflow were recorded in all patients and tissue Doppler
imaging signals in 27 patients, but FPV recordings were con-
sidered inadequate in eight patients (26%) because of inade-
Figure 2
Flow diagram of subarachnoid hemorrhage patients from admission to day 7 Flow diagram of subarachnoid hemorrhage patients from admission to day 7
Table 1
Clinical characteristics
Age, years (mean ± SD) 48 (± 12)
Female sex, n (%) 20 (65%)
Body mass index (mean ± SD) 22.8 (± 3.2)
Body surface area, m2 (mean ± SD) 1.70 (± 0.17)
Fisher scale (1/2/3/4), n (%) 1 (3%)/10 (32%)/6 (20%)/14 (45%)
WFNS score (1/2/3/4/5), n (%) 14 (45%)/9 (30%)/2 (6%)/2 (6%)/4 (13%)
Aneurysm position, n (%)
ICA 6 (19%)
MCA 9 (30%)
AComA/ACA 10 (32%)
BA 2 (6%)
PCA 1 (3%)
VA 3 (10%)
ACA = anterior cerebral artery; AcomA = anterior communicating artery; BA = basilar artery; ICA = internal carotid artery; MCA = middle cerebral 
artery; PCA = posterior cerebral artery; SD = standard deviation; VA = vertebral artery; WFNS = World Federation of Neurosurgical Societies.Critical Care    Vol 13 No 3    Meaudre et al.
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quate signal. All 31 patients had LVEF more than 50%. Of the
31 patients in the study, E/Ea was less than 8 in 30 patients
(97%) on day 1, in 29 patients (94%) on day 2, and in all
patients on day 7. Of the 23 patients recorded, E/FPV was
less than 1.5 in 21 patients (87%). In all patients, DT was more
than 130 ms and IRVT was more than 50 ms in the three
echocardiographic exams. On days 1, 2, and 7, there were no
correlations between BNP and the following echocardio-
graphic parameters: mitral E/A, E/Ea, E/FPV, DT, PAP, LV
mass, blood pressure, and IVRT (Figure 4). No significant dif-
ferences in echocardiographic data were observed between
the three study days. Of the seven patients (23%) with E/A
less than 1 on day 1, five had the same mitral inflow profile on
days 2 and 7. The other two patients had E/A more than 1 on
day 7.
Troponin Ic
The cTi level ranged from 0 to 3.67 μg/L. The proportion of
patients with cTi more than 0.14 μg/L was higher on the first
two days (22%, n = 7) than during the following days: 6% (n
= 2) on days 3 and 4, and only 3% (n = 1) on and after day 5.
The BNP level was higher in patients with cTi more than 0.14
μg/L, and the difference on day 2 was significant (106 ng/L
versus 345 ng/L) (Table 5). There was a significant correlation
between the cTi level on day 2 and the BNP level on day 2 (r
= 0.63, P < 10-3; Figure 4.) and on day 3 (r = 0.44, P < 0.05).
The three patients with cTi more than 0.9 μg/L presented an
interesting BNP time course. Only in these cases, the peak
BNP level was more than 300 ng/L. Of the four patients with
BNP more than 100 ng/L on day 7, three had a cTi more than
0.9 μg/L on day 1. There were no significant differences in cTi
levels between patients receiving norepinephrine or not during
the first three days, between patients mechanically ventilated
or not at admission, between two groups of WFNS score (1
versus 2 to 5), between men and women, or between Fisher
group 1 to 2 and group 3 to 4.
Discussion
To our knowledge, this is the first study focused on cardiac
injury due to aneurysmal SAH in patients without pre-existing
chronic hypertension and cardiac disease. The present study
demonstrated that 80% of patients develop a BNP level of
more than 100 ng/L during the first three days (peak on day 2)
after admission for aneurysm rupture, with a return to normal
levels in less than one week. Nevertheless, contrary to our
hypothesis, the BNP rise was not triggered by an elevation in
echo-estimated LVFP due to diastolic dysfunction. Moreover,
BNP and cTi seem to be more sensitive to cardiac stress
occurring in SAH as compared with Doppler variables of
diastolic function.
Strong arguments favor the idea that BNP elevation is the
result of intrinsic conditions of SAH but not the result of iatro-
genic volume overload, especially during the first three days:
standardized protocol without prophylactic hypervolemia, neg-
ative fluid balance, and near-zero sodium balance. Moreover,
the rise of the BNP level during the first three days could not
be influenced by the vasospasm because all cases have
occurred after day 5. Our study is adds to the information from
prior publications for two reasons. First, previous works have
only assessed diastolic function (categorized as normal,
impaired relaxation, pseudonormal, or restrictive) but not echo-
estimated LVFP [10,14]. Second, patients with a history of
hypertension were not excluded in these studies, in contrast to
ours. They found that patients with a history of hypertension
had higher mean BNP levels than patients without hyperten-
sion and a higher frequency of diastolic dysfunction, with no
possibility to differentiate between BNP elevation caused by
Table 2
Clinical events until day 7
ECG abnormalities, n (%) 11 (36%)
Coiled, n (%) 29 (94%)
on day 1 23
on day 2 5
on day 6 1
Craniotomy, n (%) 2 (6%)
on day 1 2
Vasospasm, n (%) 6 (19%)
Rebleeding, n (%) 1 (3%)
Hydrocephalus (derivated), n (%) 13 (42%)
Norepinephrine (used during days 1–3) 13 (42%)
Mechanical ventilation (day 1/day 7), n (%) 15 (48%)/5 (16%)
Table 3
Natremia (mean ± standard deviation), fluid balance, and sodium balance (median, interquartile range) during the first four days.
Day 1 Day 2 Day 3 Day 4
Natremia (mmol/L) 140 ± 5 141 ± 7 142 ± 7 142 ± 8
Fluid balance (mL) -750 (-975 to 275) -650 (-1475 to 650) -500 (-1250 to 100) -700 (-1100 to 400)
Sodium balance (mEq) 136 (-59 to 221) 1 (-102 to 182) -34 (-136 to 136) -51 (-144 to 41)Available online http://ccforum.com/content/13/3/R76
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chronic cardiac abnormalities and BNP related to acute neu-
rocardiac injury [6].
Although we did not use a pulmonary artery catheter, indices
of cardiac filling pressures (E/Ea and E/FPV) were not ele-
vated in our subjects on days 1, 2, and 7 (Table 4) and were
not correlated with BNP levels. In fact, it has been clearly dem-
onstrated that mitral E/Ea less than 8 and E/FPV less than 1.5
accurately predict normal LVFP [4,5]. Although no previous
work has studied filling pressure in this type of population,
other researchers have reported hemodynamic findings in line
with our findings in SAH patients by using a pulmonary artery
catheter placed for SAH management, mainly to prevent or
treat cerebral vasospasm. The studies did not find elevated
pulmonary artery wedge pressure (PAWP) during the first
week after aneurysm rupture in patients without cardiac failure
[18-21]. Mayer and colleagues [20] did not find elevated
PAWP (12.4 ± 3.5 mmHg), although patients had been man-
aged in a mildly volume-expanded state.
BNP is not only synthesized in response to cardiac mechanical
stretch [22]. The precursor of BNP is released during myocyte
stress concerning the LV or the right ventricle: heart failure
(when the ventricles are dilated, hypertrophic, or subject to
increased wall tension), acute coronary syndromes, pulmonary
disease (e.g., acute respiratory distress syndrome, lung dis-
ease with right heart failure), pulmonary embolism, high output
states (e.g., sepsis, cirrhosis, hyperthyroidism), and atrial fibril-
lation [23].That is why the BNP level lacks specificity in critical
care patients [24].
Recently, BNP was established as a sensitive prognostic
parameter in patients with acute coronary syndromes [25] and
even in asymptomatic persons [26]. In addition, transient myo-
cardial ischemia results in an immediate increase in BNP
[27,28]. Furthermore, the magnitude of the increase is propor-
tional to the severity of ischemia [28]. Tung and colleagues
[10] reported a correlation between levels of BNP and tro-
ponin release during SAH, and our findings are consistent with
that study. In fact, we found a strong correlation between cTi
and BNP levels during the first three days after aneurysm rup-
ture. However, we observed a BNP increase without myocar-
dial necrosis in 65% of our patients. Several studies have
reported that BNP is not only increased in necrotic myocardial
tissue but also in non-necrotic myocardial tissue, such as in
unstable angina, and that BNP levels reflect the severity of
myocardial damage and thus might have diagnostic value
[29,30]. Some authors have reported that elevated BNP or N-
terminal pro-brain natriuretic peptide levels are sensitive and
specific parameters for ischemia diagnosis [27,31,32]. Foote
and colleagues [27] reported that the BNP level is a marker of
inducible ischemia that is twice as sensitive for the detection
of ischemia than is ST-segment depression on exercise elec-
trocardiography. Bassan and colleagues [33] reported that
plasma BNP is an early marker of acute myocardial infarction
in patients with chest pain and non-diagnostic ECG, particu-
larly if initial creatine-kinase MB and/or troponin Ic are non-
diagnostic [33]. In these studies, the cut-off value of BNP for
myocardial events was about 100 pg/mL, similar to our BNP
levels [28,33].
It is tempting to extrapolate these results to myocardial injury
related to SAH. However, the time course of BNP release and
the mechanisms of myocardial damage are different. Reduced
regional myocardial blood flow leads to myocardial ischemia
with a cascade of changes, during which BNP could be an
early marker to detect reduced myocardial blood flow [27,33].
It was not the case in our study where BNP rise did not occur
earlier. Moreover, SAH patients have cardiac injury with normal
myocardial perfusion, without angiographic evidence of coro-
Figure 3
Daily median B-type natriuretic peptide (BNP) levels in 31 subarachnoid hemorrhage (SAH) patients without pre-existing chronic hypertension or  cardiac disease Daily median B-type natriuretic peptide (BNP) levels in 31 subarachnoid hemorrhage (SAH) patients without pre-existing chronic hypertension or 
cardiac disease.  Error bars indicate confidence intervals.Critical Care    Vol 13 No 3    Meaudre et al.
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nary artery disease or vasospasm [34-36], and without myo-
cardial hypoperfusion at the epicardial or microvascular level
[37]. However, the most likely cause of cardiac dysfunction
after SAH is excessive catecholamine release within the myo-
cardium. Masuda and colleagues [37] demonstrated
extremely enhanced sympathetic activity and a massive
release of catecholamines from the terminals of sympathetic
nerves. Massive increase in myocardial tissue occurs [36,37],
but serum catecholamine levels remain relatively unchanged,
without correlation with cTi [36]. Catecholamine and hemody-
namic parameters (heart rate, arterial pressure) peak at five
minutes and return to baseline at 30 minutes [37]. It is there-
fore logical to assume that these effects had disappeared at
the time of admission of patients several hours after the rup-
ture of the aneurysm. The absence of increase in E/Ea and E/
FPV does not exclude cardiac injury mediated by catecho-
lamine release. Actually, it is believed that high interstitial con-
centrations of norepinephrine result in myocyte calcium
overload and cell death [36]. This local phenomenon could
explain the delayed secretion of BNP.
It has been suggested that the pathophysiology of neurogenic
cardiac injury after SAH is probably similar to apical ballooning
syndrome (ABS) (Tako-Tsubo or stress cardiomyopathy)
[36,38]. Although there are very few reports of BNP levels dur-
ing ABS, the published results are similar to our findings in
many aspects. First, a marked increase in BNP has been
observed in ABS [39-41]. Second, the BNP rise is not trig-
gered by an elevation in LVFP. In two different studies, Akashi
and colleagues [39,40] reported an increase in BNP to mean
values of 522.5 pg/ml and 629.6 pg/ml, respectively, whereas
the LVFPs were low. Third, the BNP release kinetics observed
in the case report of Nef and colleagues [41] were in complete
agreement with our findings with a delayed peak in serum NT-
proBNP level observed 24 hours after the onset of clinical
symptoms. In most patients, BNP levels returned to normal
within one week [39-41].
Limitations section
The present study is notable in that it consists of carefully
selected consecutive patients from a single center. However,
the external validity of the study is strongly reduced because
of selection criteria of our patients. First, we have excluded
patients admitted 48 hours after the occurrence of aneurysm
rupture symptoms to observe cardiac injury that occurs and
develops imediately after it. It is well known that a delay in
referral to neurosurgical hospital is frequent, which could
potentially lead to a lag in the BNP and diastolic profile. Sec-
ond, this patient selection does not allow extension of the
results to all SAH patients, who are frequently hypertensive,
and have higher BNP levels than patients without hypertension
and a higher frequency of diastolic dysfunction [10]. Although
it is possible that patients slightly or recently hypertensive have
been included (unknown hypertension), our results show
strong arguments to say that they did not have chronic hyper-
Figure 4
Correlations on day 2 between BNP, cTi, E/Ea, and E/FPV Correlations on day 2 between BNP, cTi, E/Ea, and E/FPV  (a) B-type 
natriuretic peptide (BNP) vs troponin Ic (cTi); (b) BNP vs early transmi-
tral velocity (E)/tissue Doppler imaging early diastolic velocity (Ea); (c) 
E/color M-mode-derived flow propagation velocity (FPV).Available online http://ccforum.com/content/13/3/R76
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tensive heart disease (diastolic dysfunction) at the time of
admission considering the normal renal function on day 2, and
echographic data and BNP levels normal on day 7.
Conclusions
Using Doppler echocardiography, this study demonstrates
that BNP rises gradually over two days and returns to normal
within a week after SAH, without echo-estimated LVFP eleva-
tion. It provides novel evidence that levels of BNP and troponin
Ic are correlated. Furthermore, the kinetics of BNP release
appears to be close to those observed in ABS, which could
provide an additional argument that cardiac injury is catecho-
lamine-induced during SAH.
Key messages
￿  BNP rises gradually over two days and returns to nor-
mal within a week after SAH.
￿  Levels of BNP and troponin Ic are correlated in SAH 
patients.
￿  Doppler echocardiography showed that echo-estimated 
LVFP remains low during the first week after SAH.
Table 4
Hemodynamic characteristics and Doppler parameters (mean ± standard deviation)
Day 1 Day 2 Day 7
Systolic BP, mmHg 128 (± 10) 136 (± 11) 132 (± 29)
Diastolic BP, mmHg 61 (± 7) 65 (± 7) 67 (± 8)
Heart rate, beats/min 76 (± 11) 76 (± 11) 82 (± 10)
LV ejection fraction (%) 67 (± 9) 65 (± 8) 70 (± 7)
LV end-systolic volume (ml) 31 ± 5 31 ± 3 25 ± 5
LV end-diastolic volume (ml) 94 ± 16 90 ± 14 91 ± 18
Systolic PAP, mmHg 19 (± 9) 16 (± 9) 16 (± 8)
LV mass (g/m2)1 1 1  ( ±  2 5 ) - -
Mitral E (cm/s) 88 (± 21) 96 (± 22) 83 (± 16)
Mitral A (cm/s) 67 (± 20) 68 (± 20) 70 (± 20)
Mitral E/A ratio 1.32 (± 0.4) 1.47 (± 0.43) 1.29 (± 0.38)
Ea, lateral annulus (cm/s) 17.1 (± 6.5) 17.2 (± 4.8) 16.3 (± 3.2)
E/Ea 5.4 (± 1.5) 5.8 (± 1.2) 5.1 (± 0.9)
FPV (cm/s) 74 (± 15) 77 (± 12) 77 (± 10)
E/FPV 1.27 (± 0.4) 1.25 (± 0.3) 1.1 (± 0.2)
Deceleration time (ms) 206 (± 50) 206 (± 37) 200 (± 39)
Isovolumic relaxation time (ms) 79 (± 21) 77 (± 17) 77 (± 19)
A = late transmitral velocity; BP = blood pressure; E = early transmitral velocity; Ea = tissue Doppler imaging early diastolic velocity; FPV = color 
M-mode-derived flow propagation velocity; LV = left ventricular; PAP = pulmonary artery pressure.
Table 5
BNP level with or without myocardial necrosis during the first seven days (mean ± standard deviation)
BNP
day 1
BNP
day 2
BNP
day 3
BNP
day 4
BNP
day 5
BNP
day 6
BNP
day 7
cTi <0.14 μg/L (n = 24) 72 (± 66) 106 (± 66) 119 (± 104) 116 (± 92) 70 (± 98) 53 (± 42) 51 (± 73)
cTi = 0.14 μg/L
(n = 7)
116 (± 128) 345 (± 221)* 271 (± 323) 113 (± 97) 111 (± 113) 122 (± 130) 101 (± 129)
*P < 0.001 (Mann-Whitney test)
BNP = B-type natriuretic peptide; cTi = troponin Ic.Critical Care    Vol 13 No 3    Meaudre et al.
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